FBS Origin Comparison
South America, Australia, the US, Mexico, Chile, Argentina or New Zealand — a fact-based comparison of FBS sourcing origins, covering BSE/TSE status, regional viral prevalence and import documentation, to help you choose the right origin for your regulatory requirements.
Same BSE/TSE Status
South America, Australia, the US, Mexico, Chile, Argentina and New Zealand all hold WOAH "negligible BSE risk" status — the most favourable classification.
Region-Specific Viral Profiles
Viral prevalence varies meaningfully by region — not by BSE status — and is the more relevant factor for sourcing decisions.
Made in Germany, Every Origin
Regardless of raw serum origin, every batch is processed, filtered and quality-controlled in Germany.
Origin On Request
South America is our standard origin for availability; other origins can be sourced on request for specific regulatory needs.
Why FBS origin matters less — and more — than you might think
Country of origin is one of the most discussed, and most misunderstood, factors in FBS sourcing. Many procurement decisions default to a specific country on the assumption that geographic origin alone determines product safety — but the regulatory data tells a more nuanced story.
On BSE (bovine spongiform encephalopathy) risk specifically, the World Organisation for Animal Health (WOAH) classifies South America, Australia, the United States, Mexico, Chile, Argentina and New Zealand identically: all hold "negligible BSE risk" status, the most favourable tier available. From a BSE standpoint, there is no regulatory advantage to choosing one of these origins over another.
Where origins genuinely differ is in regional viral prevalence. Bovine Viral Diarrhea Virus (BVDV), for example, includes strains detected predominantly in the Americas, while regions such as New Zealand report a comparatively narrow range of cattle-borne viruses of concern. This is why SeamlessBio tests every batch — regardless of origin — for mycoplasma and BVDV (active virus and antibodies as standard, with RNA/qPCR testing available on request), rather than relying on origin alone as a safety proxy.
A further, often overlooked factor is import and re-import documentation: some destination markets impose additional testing or paperwork requirements depending on the country of collection, independent of the underlying biological risk. This is one of the practical reasons SeamlessBio sources flexibly across multiple origins, rather than committing to a single country.
Origin overview
| Origin | WOAH BSE status | Availability |
|---|---|---|
| South America | Negligible risk | Standard — highest availability |
| Australia | Negligible risk | On request |
| United States | Negligible risk | On request |
| Mexico | Negligible risk | On request |
| Chile | Negligible risk | On request |
| Argentina | Negligible risk | On request |
| New Zealand | Negligible risk | On request |
BSE status per current WOAH (World Organisation for Animal Health) classification. All batches are processed and quality-controlled in Germany regardless of origin.
How to choose the right origin for your application
For most cell culture applications, validated lot performance — not country of origin — is the strongest predictor of how FBS will behave in your specific cell lines. Origin becomes the decisive factor primarily in two situations:
When origin matters most
- Regulatory submissions with a specified country requirement
- Funding or sponsor mandates tied to a particular origin
- Avoiding specific regional viral exposures for your application
- Import documentation requirements in your destination market
- Institutional or IACUC-level sourcing policies
Need FBS from a specific origin?
Contact our team to discuss origin-specific sourcing, regulatory documentation and batch availability for your application.
Contact Us
English 
Deutsch